NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation an

Data reported at the 2022 Annual Meeting of the American Society for Clinical OncologyNBTXR3 is being developed as a product candidate with potential to integrate across the standards of care in oncology, and these data from collaborator-sponsored phase 1b/2 studies add support for the radioenhancer in combination w...

Related Keywords

United States , Cambridge , Cambridgeshire , United Kingdom , American , Brandon Owens , Kate Mcneil , Pierre Louis Germain , Linkedin , French Financial Markets Authority Autorit , Communications Department , Twitter , Investor Relations Department , Nasdaq , Exchange Commission , Pharmaengine Inc , Euronext , American Society , Regulatory News , Clinical Oncology , Laurent Levy , Comprehensive Approach , Locally Advanced Head , Neck Cancer Inclusive , Concurrent Chemoradiation , Locally Advanced , Recurrent Head , Neck Squamous Cell Carcinoma , Neoadjuvant Setting , Unresectable Rectal Cancer , Private Securities Litigation Reform Act , Annual Report , French Financial Markets Authority , Des March , Half Year Financial Report ,